Analysis on the efficacy and safety of chemotherapy combined with or without bevacizumab after CRS+HIPEC in patients with malignant peritoneal mesothelioma: a single-center retrospective study

April 16, 2026 | Comments Off on Analysis on the efficacy and safety of chemotherapy combined with or without bevacizumab after CRS+HIPEC in patients with malignant peritoneal mesothelioma: a single-center retrospective study

Frontiers in Oncology 2026 February 3 [Link] Zhi-Ran Yang, Xin-Li Liang, Xin-Bao Li, Xin-Jing Zhang, He-Liang Wu, Yan-Dong Su, Yan Li, Song-Lin An Abstract Objective: To investigate the efficacy and…

Optimising response to immunotherapies in pleural mesothelioma: clinical data and alternative models for the evaluation of new strategies

April 15, 2026 | Comments Off on Optimising response to immunotherapies in pleural mesothelioma: clinical data and alternative models for the evaluation of new strategies

Thorax 2026 February 17 [Link] Christophe Blanquart, Arnaud Scherpereel Abstract Background: Pleural mesothelioma (PM) is a rare tumour, usually associated with previous asbestos exposure. Standard frontline, pemetrexed/platinum-based chemotherapy has been…

The Role of Dosimetric Parameters in Radiation Pneumonitis: A Functional Approach in Adjuvant Treatment of Malignant Pleural Mesothelioma

April 14, 2026 | Comments Off on The Role of Dosimetric Parameters in Radiation Pneumonitis: A Functional Approach in Adjuvant Treatment of Malignant Pleural Mesothelioma

Cancers 2026 January 27 [Link] Luca Dominici, Davide Franceschini, Mauro Loi, Ruggero Spoto, Antonio Marco Marzo, Beatrice Marini, Mariya Boyanova Ilieva, Nicola Lambri, Francesco La Fauci, Ciro Franzese, Marta Scorsetti…

SATB2 Induces Malignant Transformation and Cancer Stem Cell Characteristics, and Inhibition of Its Expression Reverses Drug Resistance in Mesothelioma

April 13, 2026 | Comments Off on SATB2 Induces Malignant Transformation and Cancer Stem Cell Characteristics, and Inhibition of Its Expression Reverses Drug Resistance in Mesothelioma

Cells 2026 February 2 [Link] Cynthia Brown, Shivam Srivastava, Rohit Srivastava, Rashmi Srivastava, Jason Morvant, Anju Shrivastava, Rakesh K Srivastava Abstract SATB2 (special AT-rich binding protein 2) functions as a…

Radiofrequency Ablation for Recurrent Pleural Mesothelioma

April 10, 2026 | Comments Off on Radiofrequency Ablation for Recurrent Pleural Mesothelioma

Cancers 2026 January 26 [Link] Hiroshi Kodama, Kozo Kuribayashi, Haruyuki Takaki, Kosuke Matsuda, Takashi Shinkai, Reona Wada, Atsushi Ogasawara, Masaki Hashimoto, Daichi Fujimoto, Toshiyuki Minami, Soichiro Funaki, Takashi Kijima, Koichiro…

The Role of Dosimetric Parameters in Radiation Pneumonitis: A Functional Approach in Adjuvant Treatment of Malignant Pleural Mesothelioma

April 9, 2026 | Comments Off on The Role of Dosimetric Parameters in Radiation Pneumonitis: A Functional Approach in Adjuvant Treatment of Malignant Pleural Mesothelioma

Cancers 2026 January 27 [Link] Luca Dominici, Davide Franceschini, Mauro Loi, Ruggero Spoto, Antonio Marco Marzo, Beatrice Marini, Mariya Boyanova Ilieva, Nicola Lambri, Francesco La Fauci, Ciro Franzese, Marta Scorsetti…

BAP-1 in the diagnosis of malignant pleural mesothelioma

April 8, 2026 | Comments Off on BAP-1 in the diagnosis of malignant pleural mesothelioma

Respiratory Medicine and Research 2025 November 28 [Link] Irene Sansano, Ana Vázquez, Oscar Persiva, Marc Simó, Leire Sánchez, Pilar Montoya, Carme Dinarès, Carmen Alemán Abstract Background: The diagnosis of malignant…

Validation of chemoresistance phenotypes in pleural mesothelioma across 2D, 3D, and in vivo models

April 7, 2026 | Comments Off on Validation of chemoresistance phenotypes in pleural mesothelioma across 2D, 3D, and in vivo models

Scientific Reports 2026 February 11 [Link] Huaikai Shi, Sakthi Priya Selvamani, Richard Zelei, Ling Zhuang, Dongwei Wang, Ben Johnson, Vivek Dharwal, Duo Xu, Yiwei Wang, Tristan Rutland, Sonja Klebe, Steven…

Feasibility of multimodality treatment, including pleurectomy decortication, in carefully selected patients with sarcomatoid mesothelioma

April 6, 2026 | Comments Off on Feasibility of multimodality treatment, including pleurectomy decortication, in carefully selected patients with sarcomatoid mesothelioma

Translational Lung Cancer Research 202t6 January 31 [Link] Moshe Lapidot, Emanuele Mazzola, Raphael Bueno Abstract Background: Pleural mesothelioma (PM) represents an uncommon and exceptionally lethal malignancy. The sarcomatoid subtype constitutes…

Construction and validation of a prognostic risk score model for malignant mesothelioma

April 3, 2026 | Comments Off on Construction and validation of a prognostic risk score model for malignant mesothelioma

Discover Oncology 2026 February 8 [Link] Qingzheng An, Fengyun Cui, Guangming Shi, Longkun Ni, Kun Xiao, Feng Tian, Yuezhi Chen, Leping Li, Changqing Jing, Guodong Lian Abstract Purpose: Malignant mesothelioma…

Categories